Story perspectives

New Test Detects Ovarian Cancer Resistance Early

10/2/2025

33 6

Summary

Story summary

Memorial Sloan Kettering Cancer Center introduced CloneSeq-SV, a cfDNA-based method tracking tumor evolution in high-grade serous ovarian cancer (HGSOC).
In 18 HGSOC patients, CloneSeq-SV detected resistant populations even at the start of treatment.
The method combines single-cell whole-genome sequencing with structural variant analysis to track tumor subpopulations.
It enables earlier recurrence detection and supports personalized treatment, highlighting complex, heterogeneous resistance.

1 of 1

Story summary

Memorial Sloan Kettering Cancer Center introduced CloneSeq-SV, a cfDNA-based method tracking tumor evolution in high-grade serous ovarian cancer (HGSOC).
In 18 HGSOC patients, CloneSeq-SV detected resistant populations even at the start of treatment.
The method combines single-cell whole-genome sequencing with structural variant analysis to track tumor subpopulations.
It enables earlier recurrence detection and supports personalized treatment, highlighting complex, heterogeneous resistance.